Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is conducting a Phase 3 study titled ‘A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults.’ This study aims to assess the safety, tolerability, and immune response of a Respiratory Syncytial Virus (RSV) prefusion F subunit vaccine when administered alongside a herpes zoster subunit vaccine in adults aged 50 and above. The significance of this study lies in its potential to enhance vaccine efficacy and convenience for older adults.
The study is testing two biological interventions: the RSV prefusion F subunit vaccine and the herpes zoster subunit (HZ/su) vaccine. Both are administered via intramuscular injection and are intended to prevent RSV and shingles, respectively.
This interventional study follows a randomized, parallel-group design with no masking, focusing primarily on prevention. Participants are divided into two groups: one receiving both vaccines simultaneously and the other receiving them sequentially.
The study began on April 4, 2025, with primary completion expected shortly thereafter. The latest update was submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Pfizer’s ongoing study could influence its stock performance positively by showcasing its commitment to advancing adult vaccination. This could also impact investor sentiment, especially as the pharmaceutical industry remains competitive with ongoing innovations in vaccine development.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.